Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slices ex vivo

Tadeusz Frankiewicz1, Chris G Parsons

  • 1Department of Preclinical Research & Development, Merz Pharmaceuticals GmbH, Eckenheimer Landstrasse 100, 60318 Frankfurt/Main, Germany.

Neurotoxicity Research
|April 28, 2004
PubMed

Insights

Memantine, an NMDA receptor antagonist, did not reduce chemically-induced ischemic tolerance in rat brain slices. Therapeutically relevant doses of memantine even tended to enhance this neuroprotective effect.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Ischemic tolerance is a neuroprotective state against neuronal damage.
  • N-methyl-D-aspartate (NMDA) receptors play a role in excitotoxicity and neuronal plasticity.

Purpose of the Study:

  • To investigate the effect of memantine, an NMDA receptor antagonist, on chemically induced ischemic tolerance.
  • To determine if therapeutically relevant doses of memantine block neuroprotection against hypoxia/hypoglycemia.

Main Methods:

  • Induction of ischemic tolerance using 3-nitropropionic acid (3-NP) in rat hippocampal slices.
  • Assessment of extracellular field excitatory postsynaptic potentials (fEPSPs) suppression.
  • Pre-treatment with memantine or (+)MK-801 via Alzet minipumps.

Main Results:

  • 3-NP preconditioning significantly protected against hypoxia/hypoglycemia-induced fEPSP suppression (62.2%).
  • Memantine pre-treatment (20 mg/kg/day) tended to enhance recovery further (89.7%) without affecting basal fEPSPs.
  • (+)MK-801 pre-treatment (2 mg/kg/day) reduced ischemic tolerance (45.3%).

Conclusions:

  • NMDA receptors are involved in chemically-induced ischemic tolerance.
  • Semi-chronic pre-treatment with therapeutically relevant doses of memantine does not block, but may enhance, ischemic tolerance.

Related Concept Videos